Liminatus Pharma Inc. Class A Common Stock (LIMN)
Stock · NASDAQ · Health Care
$3.04as of 10/16/2026
Price chart
Active signals
LIMN Signal Track Record
How signals performed across all stocks →What LIMN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 4 | -5.0% | 25% | August 14, 2026 |
| Bollinger Band Breakout | 3 | -20.0% | 0% | August 13, 2026 |
| Any 20-session window (baseline) | -10.5% | 31% |
Computed by MarketWall from daily closing prices since February 18, 2026. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LIMN
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 1
- Website
- liminatuspharma.com/
Fundamentals
- 1-day range
- $3.01$3.25
- Market cap
- $6.64M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-27.15
- Dividend yield
- —
- Beta
- 0.75
- Avg. volume
- 237.6K
Liminatus Pharma Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- LIMNLiminatus Pharma Inc. Class A Common Stock$3.04▼ 5.30%Market cap $6.64MP/E —$3.25$141.5
- PMCBPharmaCyte Biotech Inc. Common Stock$0.3402▼ 4.81%Market cap $6.34MP/E —$0.3339$1.51
- AIMAIM ImmunoTech Inc. Common Stock$0.17▲ 0.00%Market cap $7.51MP/E —$0.1605$2.79
- CELZCreative Medical Technology Holdings Inc. Common Stock$0.741▼ 9.39%Market cap $7.58MP/E —$0.62$6.25
- VIVSVivoSim Labs Inc. Common Stock$0.16▼ 5.88%Market cap $5.53MP/E —$0.1495$3.4
- BCABBioAtla Inc. Common Stock$1.36▲ 4.62%Market cap $5.53MP/E —$1.07$71.5
- CRISCuris Inc. Common Stock$0.41▼ 19.61%Market cap $8.59MP/E —$0.465$33.6
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LIMN Liminatus Pharma Inc. Class A Common Stock | $6.64M | — | $3.04 | ▼ 5.30% | $3.25$141.5 |
| PMCB PharmaCyte Biotech Inc. Common Stock | $6.34M | — | $0.3402 | ▼ 4.81% | $0.3339$1.51 |
| AIM AIM ImmunoTech Inc. Common Stock | $7.51M | — | $0.17 | ▲ 0.00% | $0.1605$2.79 |
| CELZ Creative Medical Technology Holdings Inc. Common Stock | $7.58M | — | $0.741 | ▼ 9.39% | $0.62$6.25 |
| VIVS VivoSim Labs Inc. Common Stock | $5.53M | — | $0.16 | ▼ 5.88% | $0.1495$3.4 |
| BCAB BioAtla Inc. Common Stock | $5.53M | — | $1.36 | ▲ 4.62% | $1.07$71.5 |
| CRIS Curis Inc. Common Stock | $8.59M | — | $0.41 | ▼ 19.61% | $0.465$33.6 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Valetudo Therapeutics LLC · July 2, 2026 · J3.45M
- Valetudo Therapeutics LLC · June 24, 2026 · J4.37M
Institutional Ownership
March 31, 2026
- Total shares held
- 1.45M
- Total value held
- $184.9K
- Institutional holders
- 14
- Unknown677.5K
- Unknown350.0K
- Unknown117.8K
- Unknown71.3K
- Unknown54.6K
- Unknown50.4K
- Unknown34.7K
- Unknown27.5K
- Unknown22.0K
- Unknown19.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Liminatus Pharma Regains Nasdaq Compliance
Liminatus Pharma announced it has regained compliance with Nasdaq's minimum bid price rule. This development addresses a regulatory requirement that, if not met, can lead to delisting. The stock remains well below its 52-week high, reflecting the broader challenges the company has faced recently.
Liminatus Pharma Regains Nasdaq Compliance. Liminatus Pharma announced it has regained compliance with Nasdaq's minimum bid price rule. This development addresses a regulatory requirement that, if not met, can lead to delisting. The stock remains well below its 52-week high, reflecting the broader challenges the company has faced recently.